Cargando…

MON-089 Discovery and Identification of Late Stage Selective Nonpeptide Somatostatin Subtype 5 (sst5) Agonists for the Treatment of Hyperinsulinemic Hypoglycemia

Congenital hyperinsulinism (CHI) results from mutations within the insulin secretion pathway and is characterized by excessive and/or inappropriate insulin secretion by pancreatic islet β-cells. CHI is the most common cause of persistent hypoglycemia in newborns and infants and is estimated to affec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fowler, Melissa A, Zhao, Jian, Sturchler, Emmanuel, Rico, Elizabeth, de Necochea-Campion, Rosalia, Athanacio, Jon, Kredel, Taylor A, Antwan, Agnes, Johns, Michael, Tsivkovski, Oleg, Wang, Shmiao, Luo, Rosa, Kusnetzow, Ana Karin, Madan, Ajay, Struthers, Scott, Markison, Stacy, Zhu, Yun Fei, Betz, Stephen F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Pediatric Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7208924/ http://dx.doi.org/10.1210/jendso/bvaa046.701

Ejemplares similares

SAT-169 Selective Nonpeptide Somatostatin Subtype 5 (sst5) Agonists Suppress Glucose- and Sulfonylurea-Induced Insulin Secretion in Rats
por: Sturchler, Emmanuel, et al.
Publicado: (2019)

SAT-260 Selective Nonpeptide Somatostatin Subtype 5 (sst5) Agonists Suppress Induced Insulin Secretion in Pancreatic Islets from both Rats and Healthy Human Donors
por: Rico-Bautista, Elizabeth, et al.
Publicado: (2019)

OR19-03 Effects of Nonpeptide Orally Bioavailable ACTH Antagonists on Adrenal Gland Size and Function in Rats
por: Markison, Stacy, et al.
Publicado: (2020)

Effects of CRN04894, a Nonpeptide Orally Bioavailable ACTH Antagonist, on Corticosterone in Rodent Models of ACTH Excess
por: Fowler, Melissa A, et al.
Publicado: (2021)

Selective Somatostatin 5 (SST5) and Somatostatin 2 (SST2) Nonpeptide Agonists Potently Suppress Glucose- and Tolbutamide-Stimulated Dynamic Insulin Secretion From Isolated Human Islets
por: Rico, Elizabeth, et al.
Publicado: (2021)

MON-176 Discovery and Identification of Late Stage Selective Nonpeptide ACTH Antagonists for the Treatment of Cushing’s Disease, Ectopic ACTH Secreting Tumors, and Congenital Adrenal Hyperplasia
por: Kusnetzow, Ana Karin, et al.
Publicado: (2020)

PSUN304 CRN04777 an Oral, Nonpeptide SST5-selective Somatostatin Agonist Dose Dependently Suppresses Basal and Stimulated Insulin Secretion
por: Ferrara-Cook, Christine, et al.
Publicado: (2022)

SAT-364 Nonpeptide Orally-Bioavailable ACTH Antagonists: Suppression of ACTH-Induced Corticosterone Secretion and Adrenal Hypertrophy in Rats
por: Kusnetzow, Ana, et al.
Publicado: (2019)

Paltusotine, a novel oral once-daily nonpeptide SST2 receptor agonist, suppresses GH and IGF-1 in healthy volunteers
por: Madan, Ajay, et al.
Publicado: (2022)

SAT-429 Final Results from the First in Man Phase 1 Clinical Trial of CRN00808, an Orally Bioavailable sst2-Selective, Nonpeptide Somatostatin Biased Agonist, for the Treatment of Acromegaly: Safety, Pharmacokinetics, Pharmacodynamics, and Midazolam Drug Interaction in Healthy Volunteers
por: Madan, Ajay, et al.
Publicado: (2019)

A selective nonpeptide somatostatin receptor 5 agonist effectively decreases insulin secretion in hyperinsulinism
por: Juliana, Christine A., et al.
Publicado: (2023)

Discovery of Paltusotine (CRN00808), a Potent, Selective, and Orally Bioavailable Non-peptide SST2 Agonist
por: Zhao, Jian, et al.
Publicado: (2022)

OR23-05 Human Absorption, Metabolism, Excretion, and Absolute Oral Bioavailability of (14)C-CRN00808, an Orally Bioavailable, Nonpeptide, Selective, Somatostatin Receptor 2 (sST2) Biased Agonist for the Treatment of Acromegaly
por: Madan, Ajay, et al.
Publicado: (2020)

FRI538 Discovery And Characterization Of Orally Bioavailable Nonpeptide Thyroid Stimulating Hormone Receptor (TSHR) Antagonists For The Treatment Of Graves’ Disease
por: Fowler, Melissa A, et al.
Publicado: (2023)

SAT182 Effects Of An Orally Bioavailable Nonpeptide Parathyroid Hormone Receptor Type 1 (PTH1R) Antagonist In Rodent Models Of Primary Hyperparathyroidism (PHPT)
por: Antwan, Agnes S, et al.
Publicado: (2023)

The Truncated Isoform of Somatostatin Receptor5 (sst5TMD4) Is Associated with Poorly Differentiated Thyroid Cancer
por: Puig-Domingo, Manel, et al.
Publicado: (2014)

Epigenetic and post‐transcriptional regulation of somatostatin receptor subtype 5 (SST(5)) in pituitary and pancreatic neuroendocrine tumors
por: Pedraza‐Arevalo, Sergio, et al.
Publicado: (2021)

DOTA-Derivatives of Octreotide Dicarba-Analogs with High Affinity for Somatostatin sst(2,5) Receptors
por: Pratesi, Alessandro, et al.
Publicado: (2017)

Somatostatin Receptor Splicing Variant sst5TMD4 Overexpression in Glioblastoma Is Associated with Poor Survival, Increased Aggressiveness Features, and Somatostatin Analogs Resistance
por: Fuentes-Fayos, Antonio C., et al.
Publicado: (2022)

Structural insights into the activation of somatostatin receptor 2 by cyclic SST analogues
por: Bo, Qing, et al.
Publicado: (2022)

OR12-2 Inhibition of Basal and ACTH-stimulated Cortisol Secretion in Humans Using an Oral Nonpeptide ACTH Antagonist (CRN04894)
por: Betz, Stephen, et al.
Publicado: (2022)

Presence of sst5TMD4, a truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumors
por: Sampedro-Núñez, Miguel, et al.
Publicado: (2015)

The human brain somatostatin interactome: SST binds selectively to P-type family ATPases
por: Solarski, Michael, et al.
Publicado: (2019)

Reassessment of SST4 Somatostatin Receptor Expression Using SST4-eGFP Knockin Mice and the Novel Rabbit Monoclonal Anti-Human SST4 Antibody 7H49L61
por: Lupp, Amelie, et al.
Publicado: (2021)

LBSAT142 Discovery And Characterization Of A Potent And Orally Bioavailable Parathyroid Hormone Receptor Type-1 (PTHR1) Antagonist For The Treatment Of Hypercalcemia
por: Rico-Bautista, Elizabeth, et al.
Publicado: (2022)

Human Somatostatin SST(4) Receptor Transgenic Mice: Construction and Brain Expression Pattern Characterization
por: Nemes, Balázs, et al.
Publicado: (2021)

The truncated somatostatin receptor sst5TMD4 stimulates the angiogenic process and is associated to lymphatic metastasis and disease-free survival in breast cancer patients
por: Gahete, Manuel D., et al.
Publicado: (2016)

Neuroendocrine Carcinoma of the Uterine Cervix: A Clinicopathologic and Immunohistochemical Study with Focus on Novel Markers (Sst2–Sst5)
por: Inzani, Frediano, et al.
Publicado: (2020)

P089: Surveillance of bacterial resistance to disinfectants
por: Saperkin, N, et al.
Publicado: (2013)

In Silico, In Vitro and In Vivo Pharmacodynamic Characterization of Novel Analgesic Drug Candidate Somatostatin SST(4) Receptor Agonists
por: Kántás, Boglárka, et al.
Publicado: (2021)

Dimerization of GPCRs: Novel insight into the role of FLNA and SSAs regulating SST(2) and SST(5) homo- and hetero-dimer formation
por: Treppiedi, Donatella, et al.
Publicado: (2022)

Reassessment of somatostatin receptor SST4 expression in bronchopulmonary and gastroenteropancreatic neuroendocrine neoplasms using the novel rabbit monoclonal anti-human SST4 antibody 7H49L61
por: Ehms, Blanca, et al.
Publicado: (2022)

Early cerebral activities of the environmental estrogen bisphenol A appear to act via the somatostatin receptor subtype sst(2).
por: Facciolo, Rosa Maria, et al.
Publicado: (2002)

Case report: A particularly rare case of endogenous hyperinsulinemic hypoglycemia complicated with pregnancy treated with short-acting somatostatin analog injections
por: Barsi, Ádám, et al.
Publicado: (2022)

Urotensin-II Ligands: An Overview from Peptide to Nonpeptide Structures
por: Merlino, Francesco, et al.
Publicado: (2013)

Advances in the Development of Nonpeptide Small Molecules Targeting Ghrelin Receptor
por: Giorgioni, Gianfabio, et al.
Publicado: (2022)

PSAT089 Lack of Effect of Metformin in Murine Pheochromocytoma Model
por: Ghayee, Hans K, et al.
Publicado: (2022)

FRI089 Massive Hypertriglyceridemia? Think Oral Contraceptive Pills!
por: Ali, Israa, et al.
Publicado: (2023)

Novel B55α-PP2A mutations in AML promote AKT T308 phosphorylation and sensitivity to AKT inhibitor-induced growth arrest
por: Shouse, Geoffrey, et al.
Publicado: (2016)

Hyperinsulinemic Hypoglycemia – The Molecular Mechanisms
por: Nessa, Azizun, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_lu6pruc4m6n20a8g1e5vpdc6ea